# Abeona Therapeutics Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Abeona Therapeutics Inc).

## Overview

Abeona Therapeutics, Inc. is a U.S. commercial-stage biopharmaceutical company focused on cell and gene therapies for life-threatening diseases. Its first approved product is ZEVASKYN™ (prademagene zamikeracel; pz-cel), an autologous cell-based gene therapy approved by the FDA on April 28, 2025 for treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company is transitioning from development to commercialization, with initial sales expected to begin through specialized treatment centers in the U.S. Abeona also operates its own cGMP manufacturing capability to supply ZEVASKYN drug product for launch and ongoing demand.

## Products & services

• ZEVASKYN™ (pz-cel) for RDEB wound treatment (single application)
• ZEVASKYN™ Qualified Treatment Centers (QTC) enablement/support
• cGMP manufacturing of ZEVASKYN drug product (Cleveland, Ohio)
• Cell & gene therapy R&D and clinical development programs
• Regulatory, market access, and reimbursement execution for rare disease

- **ZEVASKYN™ (pz-cel) product sales** (70%) — Commercial sales of the FDA-approved autologous gene-modified cellular sheets for RDEB wounds via specialized treatment centers.
- **Manufacturing & supply (internal cGMP operations)** (10%) — In-house cGMP manufacturing activities and quality systems supporting commercial supply of ZEVASKYN.
- **Pipeline R&D (cell and gene therapy)** (20%) — Preclinical/clinical development and regulatory work for additional cell and gene therapy candidates beyond ZEVASKYN.

- ZEVASKYN™ (pz-cel) for RDEB wound treatment (single application)
- ZEVASKYN™ Qualified Treatment Centers (QTC) enablement/support
- cGMP manufacturing of ZEVASKYN drug product (Cleveland, Ohio)
- Cell & gene therapy R&D and clinical development programs
- Regulatory, market access, and reimbursement execution for rare disease

## Customers

Abeona’s near-term customer base is concentrated in the RDEB ecosystem, where treatment decisions are made by specialist clinicians at epidermolysis bullosa centers and paid for by third-party payers. ZEVASKYN is intended to be delivered through ZEVASKYN Qualified Treatment Centers (QTCs), which are recognized EB treatment centers with cell and gene therapy experience, making these centers a key channel partner for patient identification, administration, and follow-up. Demand depends on identifying diagnosed RDEB patients who elect to begin treatment and on physician confidence in the therapy’s benefit-risk profile. Commercial uptake is also driven by securing reimbursement, pricing, and coverage policies appropriate for a high-complexity, rare-disease gene-modified therapy.

- **Qualified Treatment Centers (QTCs) / EB specialty centers** (primary) — Serve as the primary administration sites for ZEVASKYN and drive adoption through clinical capability, patient identification, and treatment workflows.
- **Third-party payers (commercial and government)** (primary) — Provide reimbursement and coverage decisions that determine affordability, utilization management, and net pricing for ZEVASKYN.
- **RDEB patients and caregivers** (secondary) — Choose to initiate therapy and comply with treatment logistics; demand is constrained by diagnosis rates, access to QTCs, and perceived benefit.
- **Hospitals/health systems supporting QTCs** (secondary) — Enable contracting, procurement, and operational readiness for cell/gene therapy delivery and post-treatment care.

- Epidermolysis bullosa (EB) treatment centers administering ZEVASKYN
- Specialist physicians selecting therapy for RDEB wound care
- Adult and pediatric RDEB patients seeking durable wound treatment
- Commercial insurers and government payers determining coverage
- Hospital pharmacies/health systems managing procurement and logistics
- Patient advocacy and referral networks influencing diagnosis and access

## Geography

Abeona’s initial commercialization focus is the United States, where ZEVASKYN received FDA approval and where the company is establishing a network of Qualified Treatment Centers across the country to reach patients nationwide. The company operates a cGMP commercial manufacturing facility in Cleveland, Ohio to produce ZEVASKYN drug product for launch and ongoing supply. While the product has received orphan designations in the U.S. and the European Medicines Agency has granted Orphan Drug Designation, international expansion depends on additional regulatory approvals and market access execution. Cross-border trade policy, sanctions, and non-tariff measures are relevant because they can affect suppliers, international operations, and the ability to compete or attract non-U.S. partners and resources.

- United States is the initial commercial market (FDA approval April 2025)
- Nationwide U.S. access via Qualified Treatment Centers (QTCs)
- cGMP manufacturing facility located in Cleveland, Ohio
- Potential future ex-U.S. opportunity supported by EMA orphan designation
- Trade restrictions/sanctions can affect suppliers and international activity

## Strategy

The company’s top priority is executing the ZEVASKYN launch by activating QTCs, enrolling new patients, and building physician and patient awareness in a concentrated rare-disease community. A second priority is securing reimbursement, pricing, and coverage to support sustainable utilization for a specialized, autologous gene-modified therapy. Abeona is also focused on ensuring reliable cGMP manufacturing and supply chain performance to avoid shortages or quality issues that could disrupt adoption. Given its history of operating losses and reliance on equity financing, maintaining access to capital (including ATM usage and potential collaborations) remains central to funding commercialization and pipeline development.

- **Commercial launch execution for ZEVASKYN** (short-term) — Revenue and viability depend on converting FDA approval into treated patients through QTC readiness and referral pathways.
- **Market access: reimbursement, pricing, and coverage** (short-term) — Payer decisions and net pricing will determine adoption pace and realized economics in a rare-disease setting.
- **Manufacturing reliability and quality systems** (medium-term) — Autologous cell-based gene therapy supply is operationally complex; shortages or quality issues could materially impair uptake.

- Launch ZEVASKYN via QTC network and enroll new RDEB patients
- Drive market acceptance among EB specialists and treatment guidelines
- Secure reimbursement, pricing, and coverage to enable utilization
- Scale and de-risk cGMP manufacturing to prevent supply disruptions
- Protect and expand IP (patents, trade secrets, know-how) around pz-cel
- Use financing tools (ATM, debt) and partnerships to fund operations

## Risks

Abeona’s business is highly concentrated in a single newly approved product, so the timing and rate of ZEVASKYN adoption, reimbursement outcomes, and competitive developments can drive large swings in revenue and cash needs. The company faces execution risk in identifying and enrolling RDEB patients, building QTC capacity, and maintaining physician and patient confidence, particularly if safety signals, labeling changes, or negative publicity emerge. Operationally, autologous cell/gene therapy manufacturing is complex; quality failures, supply disruptions, or capacity constraints could lead to shortages and lost demand. Regulatory risk remains material, including potential disruptions at the FDA or other agencies that could delay approvals, post-approval changes, or future pipeline progress, while trade restrictions and sanctions can add compliance cost and limit international options.

- **Commercial adoption and reimbursement risk for ZEVASKYN** [critical] — The company has not recorded revenue from ZEVASKYN to date and future performance depends on market acceptance, patient identification, and payer coverage/pricing.
- **Manufacturing/supply risk for an autologous gene-modified therapy** [high] — Unexpected manufacturing issues, quality problems, or product shortages could significantly reduce revenue and disrupt the launch.
- **Regulatory disruption risk (FDA and other agencies)** [medium] — Funding shortages or operational disruptions at agencies could delay approvals, modifications, or commercialization activities.
- **Trade restrictions, sanctions, and non-tariff measures** [medium] — Tariffs, sanctions, and retaliatory measures can increase compliance burden and limit international suppliers, customers, investment, or approvals.

- Single-product concentration: ZEVASKYN commercial success drives results
- Reimbursement/pricing risk could limit uptake and net revenue
- Patient finding/enrollment risk in a small, diagnosed RDEB population
- Manufacturing and supply chain disruptions could cause shortages
- Safety, labeling changes, or product liability could reduce confidence
- Regulatory agency disruptions (e.g., FDA staffing/funding) delay actions
- IP protection loss or challenges could erode exclusivity and economics
- Trade restrictions/sanctions add compliance cost and limit partners

## Accounting

As a company transitioning into first-product commercialization, the timing of revenue recognition for ZEVASKYN will become a key driver of quarterly comparability, particularly given the low initial patient volumes and the role of reimbursement and payer adjudication in determining net revenue. Management highlights that financial reporting relies on estimates and judgments that can materially affect results, which is typical for biopharma companies with significant accruals and contingencies. Cash and investment accounting is relevant because the company invests available funds in certificates of deposit, money market funds, government securities, and investment-grade interest-bearing securities, which affects interest income and fair value disclosures. The company states it does not invest in derivative financial instruments, reducing complexity from hedge accounting but leaving results more directly exposed to operating cash burn and financing activity.

- **Revenue recognition and net revenue estimates for ZEVASKYN**
- **Critical estimates and judgments**
- **Short-term investments classification and fair value**

- Revenue recognition for ZEVASKYN will hinge on net reimbursement estimates
- High estimation uncertainty can materially change reported results
- Accruals/contingencies typical for regulated biopharma (legal/regulatory)
- Accounting for short-term investments affects interest income and FV notes
- No derivatives used, limiting hedge/derivative accounting complexity
- Quarterly results may be volatile during early commercialization ramp

---

*Last updated: 2026-09-24T12:28:32.713820+00:00*